The University of Texas MD Anderson Cancer Center and Federation Bio today announced a strategic collaboration to design and manufacture a complex, synthetic microbial consortium with the goal of expanding the number of cancer patients who respond to immunotherapy. The agreement pairs Federation Bio’s proprietary ACT™ (anerobic co-culture technology) platform with the expertise and capabilities of MD Anderson’s Platform for Innovative...
The University of Texas MD Anderson Cancer Center today announced that Eyal Gottlieb, Ph.D., has been named the institution’s vice president...
The University of Texas MD Anderson Cancer Center again supports World Cancer Research Day, Sept. 24, and its goals to highlight...
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Clinical advances include treating hematologic cancers with effective targeted therapies, circulating tumor DNA as a biomarker for recurrence with colorectal liver metastases, and using magnetic resonance imaging (MRI) to guide surgical decisions for patients...
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
Researchers at The University of Texas MD Anderson Cancer Center have discovered that two distinct classes of cancer-associated fibroblasts...
The University of Texas MD Anderson Cancer Center today launched the James P. Allison Institute, a visionary research and innovation...
A multicenter research team co-led by The University of Texas MD Anderson Cancer Center developed the first drug to treat the uncontrolled...
A new computational approach developed by researchers at The University of Texas MD Anderson Cancer Center successfully combines data from...
The University of Texas MD Anderson Cancer Center and Eisbach Bio GmbH today announced a strategic research collaboration to jointly discover...